Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Cancer patients can develop enterocolitis after antibody blockade
July 14th, 2006
According to recent research from the United States, cancer patients can develop enterocolitis after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). "CTLA4 is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. "Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented," wrote K.E. Beck and...
Source: Genomics & Genetics Weekly (2006-07-14)
|
